Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...

The incidence of breast cancer has increased from 900 000 to 2.3 million new annual cases over the last 25 years. The 5-year ...

The inability of QFR to rival FFR for 1-year MACE is a reminder of the need for large studies, even when new tech is enticing ...